In the pre-liver transplantation and post-liver transplantation cohorts 77 of 109 (71%) patients and 64 of 159 (40%) patients, respectively, achieved undetectable HBV DNA levels at week 48 (< 1,000 copies/ ml Roche Amplicor Monitor PCR assay).